Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists

被引：15
作者：
Giorgino, Francesco [1 ]
Bonadonna, Riccardo C. [2 ,3 ]
Gentile, Sandro [4 ]
Vettor, Roberto [5 ]
Pozzilli, Paolo [6 ]
机构：
[1] Univ Bari Aldo Moro, Dipartimento Emergenza & Trapianti Organi, Sez Med Interna Endocrinol Androl & Malattie Meta, Bari, Italy
[2] Univ Parma, Dipartimento Med Clin & Sperimentale, Div Endocrinol, Parma, Italy
[3] AOU Parma, Parma, Italy
[4] Univ Naples 2, Dipartimento Med Clin & Sperimentale, Naples, Italy
[5] Univ Padua, Clin Med 3, Dipartimento Med DIMED, Padua, Italy
[6] Univ Campus Biomed, Dept Endocrinol & Diabet, Rome, Italy
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2016年 / 32卷 / 06期
关键词：
GLP-1 receptor agonist; intensification; exenatide; lixisenatide; algorithms; latent autoimmune diabetes in adults (LADA); TYPE-2; DIABETES-MELLITUS; ONCE-DAILY LIXISENATIDE; PANCREATIC BETA-CELLS; OPEN-LABEL; DOUBLE-BLIND; INDUCED APOPTOSIS; DIPEPTIDYL PEPTIDASE; POSTPRANDIAL GLUCOSE; ANTIDIABETIC AGENTS; DAILY LIRAGLUTIDE;
D O I：
10.1002/dmrr.2775
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. (C) 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.
引用
收藏
页码：497 / 511
页数：15
相关论文
共 104 条
[1]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[2]  
[Anonymous], DIABETOLOGIA S1
[3]  
[Anonymous], LIR EFF ACT DIAB EV
[4]   Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study [J].
Arnolds, Sabine ;
Dellweg, Sibylle ;
Clair, Janina ;
Dain, Marie-Paule ;
Nauck, Michael A. ;
Rave, Klaus ;
Kapitza, Christoph .
DIABETES CARE, 2010, 33 (07) :1509-1515
[5]   Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review [J].
Aroda, Vanita R. ;
Henry, Robert R. ;
Han, Jenny ;
Huang, Wenying ;
DeYoung, Mary Beth ;
Darsow, Tamara ;
Hoogwerf, Byron J. .
CLINICAL THERAPEUTICS, 2012, 34 (06) :1247-1258
[6]  
AstraZeneca AB, BYETT EX SUMM PROD C
[7]   A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes [J].
Barrington, P. ;
Chien, J. Y. ;
Showalter, H. D. H. ;
Schneck, K. ;
Cui, S. ;
Tibaldi, F. ;
Ellis, B. ;
Hardy, T. A. .
DIABETES OBESITY & METABOLISM, 2011, 13 (05) :426-433
[8]   DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes [J].
Blevins, Thomas ;
Pullman, John ;
Malloy, Jaret ;
Yan, Ping ;
Taylor, Kristin ;
Schulteis, Christine ;
Trautmann, Michael ;
Porter, Lisa .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1301-1310
[9]  
Boehringer Ingelheim, TRADJ LIN PRESCR INF
[10]  
Bonadonna RC, 2014, DIABETES, V63, pA262
12345678910